Yeungnam Univ J Med Search

CLOSE


Yeungnam Univ J Med > Volume 28(1); 2011 > Article
Yeungnam University Journal of Medicine 2011;28(1):31-44.
DOI: https://doi.org/10.12701/yujm.2011.28.1.31    Published online June 30, 2011.
Early or Late Gefitinib, Which is Better for Survival?: Retrospective Analysis of 228 Korean Patients with Advanced or Metastatic NSCLC.
Dong Gun Kim, Min Kyoung Kim, Sung Hwa Bae, Sung Ae Koh, Sung Woo Park, Hyun Je Kim, Myung Jin Kim, Hyo Jin Jang, Kyung Hee Lee, Kwan Ho Lee, Jin Hong Chung, Kyung Chul Shin, Hun Mo Ryoo, Myung Soo Hyun
1Division of Oncology, Department of Internal Medicine, College of Medicine, Yeungnam University, Daegu, Republic of Korea. kmk21c@med.yu.ac.kr
2Division of Pulmonology, Department of Internal Medicine, College of Medicine, Yeungnam University, Daegu, Republic of Korea.
3Division of Oncology, Department of Internal Medicine, School of Medicine, Catholic University of Daegu, Republic of Korea.
Abstract
BACKGROUND: The optimal timing of treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKI) in NSCLC patients has not yet been determined. METHODS: We separated 228 patients with advanced/metastatic NSCLC treated with gefitinib into an early gefitinib group (patients who received gefitinib as first- or second-line treatment) and a delayed gefitinib group (patients who received gefitinib as third or fourth-line treatment) and attempted to determine whether the timing of gefitinib treatment affected clinical outcomes. RESULTS: Median overall survival (OS), progression free survival (PFS), and median OS from first-line treatment of advanced/metastatic disease (OSt) for 111 patients in the early gefitinib group were 6.2 months, 3.3 months, and 11.6 months. However, median OS, PFS, and OSt for 84 patients in the delayed gefitinib group were 7.8 months, 2.3 months, and 22.7 months. No differences in OS and PFS were observed between the 2 groups. However, OSt was significantly longer in the delayed gefitnib group. Timing of gefitinib therapy was one of the independent predictors of OSt. Hb > or = 10 g/dl, and having never smoked, and ECOG performance status < or =1 were independent predictors of better PFS. CONCLUSION: Deferral of gefitinib therapy in patients with advanced or metastatic NSCLC may be preferable if they are able to tolerate chemotherapy.
Key Words: Tyrosine kinase inhibitor, Gefitinib, Non-small cell lung cancer
TOOLS
Share :
Facebook Twitter Linked In Google+ Line it
METRICS Graph View
  • 0 Crossref
  •    
  • 39 View
  • 0 Download
Related articles in Yeungnam Univ J Med


ABOUT
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
AUTHOR INFORMATION
Editorial Office
170 Hyeonchung-ro, Nam-gu, Daegu 42415, Korea
Tel: +82-53-640-6832    Fax: +82-53-651-0394    E-mail: yujm@yu.ac.kr                

Copyright © 2019 by Yeungnam University College of Medicine. All rights reserved.

Developed in M2community

Close layer
prev next